Training Session for Physiotherapists and Occupational Therapists on Outcome Measures in Spinal muscular atrophy hosted by Quebec SMA Network
This past March, the Quebec SMA Network (Réseau québécois de l’amyotrophie spinale – RQAS) in collaboration with the NMD4C and Muscular Dystrophy Canada (MDC) hosted an interactive training session for French-speaking physiotherapists (PT) and occupational therapists (OT) on assessment measures and practices for Spinal muscular atrophy (SMA). This training gathered PTs and OTs to train and discuss SMA standardized outcome measures and work through current problems/challenges, to improve how these measures often tied to drug reimbursement are conducted.
Thank you to everyone who attended! Special thanks to Dr. Xavier Rodrigue, Sarah Turgeon Desilets, Mélanie Claveau, Monique Emond, Catherine Desautels, Isabelle Demers, Amy Loignon, and Catherine Boivin. The event report is being developed, and additional virtual and in-person English training session will be organized before the end of the year. This event would not have been possible without restricted support from Roche and Biogen.
Please contact us at and if you have any questions about SMA outcome measures or if you are a healthcare professional interested in events like this.
Read next...
Save the Date: 2027 Neuromuscular Postdoctoral Fellowship Funding Competition
The 2027 NMD4C/MDC Neuromuscular Postdoc Fellowship Funding Competition will open for applications on September 2, 2026. Our annual funding competition awards salary support for early-career scientists pursuing postdoctoral studies in neuromuscular disease research.
Spinal Muscular Atrophy (SMA) Awareness Month – Research Spotlight
August is Spinal Muscular Atrophy (SMA) Awareness Month, and we are thrilled to feature high-impact research led by members of the NMD4C community!
Published recently in Annals of Neurology, a study titled “Maternal-Fetal Administration of Risdiplam Partially Rescues the SMNΔ7 Mouse Model of Spinal Muscular Atrophy” explores the potential of early prenatal therapeutic interventions for SMA.
